In part IV of the NextBio tutorials, we use the Clinical Trials and Meta-analysis apps to explore the effects of the drug tibolone
High through-put technology is churning out data faster than human beings can process and sift through this abundance of information. However, not all of the results obtained are included in the finished product of a study. A recent paper by Lisa Bero and her colleagues investigates the effect of omitted trial outcome data from the Food and Drug Administration. By examining studies included in the Cochrane reviews, the researchers found that approximately half of these clinical trials exclude data. Meta-analyses and systemic reviews based on partial data may overestimate the efficacy of the drug, a practice that can be harmful to patients. Bero and her colleagues found that 19 out of 41 trials included in their reanalysis showed decreased efficacy with the addition of unpublished data. Read more…

